Digoxin at sub-cardiotonic dose modulates the anticonvulsive potential of valproate, levetiracetam and topiramate in experimental primary generalized seizures.

The prevalence of epilepsy in the world population together with a high percentage of patients resistant to existing antiepileptic drugs (AEDs) stimulates the constant search for new approaches to the treatment of the disease. Previously a significant anticonvulsant potential of cardiac glycoside digoxin has been verified by enhancing a weak activity of AEDs in low doses under screening models of seizures induced by pentylenetetrazole and maximal electroshock. The aim of the present study is to investigate the influence of digoxin at a sub-cardiotonic dose on the anticonvulsant activity of valproate, levetiracetam, and topiramate in models of primary generalized seizures with different neurochemical mechanisms. A total of 264 random-bred male albino mice have been used. AEDs were administered 30 min before seizure induction once intragastrically at conditionally effective (ED50) and sub-effective (½ ED50) doses: sodium valproate and topiramate - at doses of 300 and 150 mg/kg; levetiracetam - at doses of 100 and 50 mg/kg. Digoxin was administered once subcutaneously at a dose of 0.8 mg/kg body weight (1/10 LD50) 10-15 min before seizure induction. Picrotoxin (aqueous solution 2.5 mg/kg, subcutaneously), thiosemicarbazide (aqueous solution 25 mg/kg, intraperitoneally), strychnine (aqueous solution 1.2 mg/kg, subcutaneously), camphor (oil solution 1000 mg/kg, intraperitoneally) have been used as convulsive agents for seizure induction. It was found that under the conditions of primary generalized seizures induced by picrotoxin, thiosemicarbazide, strychnine, and camphor, digoxin not only shows its own strong anticonvulsant activity but also significantly enhances the anticonvulsant potential of classical AEDs sodium valproate, levetiracetam, and topiramate. The obtained results substantiate the expediency of further in-depth study of digoxin as an anticonvulsant drug, in particular, the in-depth study of neurochemical mechanisms of its action.

[1]  S. Shtrygol’,et al.  Low-dose digoxin enhances the anticonvulsive potential of carbamazepine and lamotrigine in chemo-induced seizures with different neurochemical mechanisms , 2021, ScienceRise: Pharmaceutical Science.

[2]  S. Czuczwar,et al.  Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it , 2021, Expert opinion on drug metabolism & toxicology.

[3]  L. Rocha,et al.  Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources , 2019, Epilepsy & Behavior.

[4]  S. Shtrygol’,et al.  Digoxin enhances the effect of antiepileptic drugs with different mechanism of action in the pentylenetetrazole-induced seizures in mice , 2020, Epilepsy Research.

[5]  A. Abdelsameea,et al.  Effects of Diclofenac Versus Meloxicam in Pentylenetetrazol-Kindled Mice , 2020, Neurochemical Research.

[6]  K. Kuča,et al.  Digoxin: Pharmacology and toxicology-A review. , 2020, Environmental toxicology and pharmacology.

[7]  W. Löscher The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments , 2020, Neuropharmacology.

[8]  M. Rogawski,et al.  Mechanisms of action of currently used antiseizure drugs , 2020, Neuropharmacology.

[9]  E. Perucca Antiepileptic drugs: evolution of our knowledge and changes in drug trials. , 2019, Epileptic disorders : international epilepsy journal with videotape.

[10]  A. Gebre,et al.  The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure , 2019, Behavioural neurology.

[11]  Xuezheng Sun,et al.  The epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis , 2018, Epilepsia.

[12]  L. Moscote-Salazar,et al.  The Effect of Statins in Epilepsy: A Systematic Review , 2018, Journal of Neurosciences in Rural Practice.

[13]  D. Yusuf,et al.  Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy , 2018, BMC Neurology.

[14]  Masahiko Watanabe,et al.  Anticonvulsant effects of acetaminophen in mice: Comparison with the effects of nonsteroidal anti-inflammatory drugs , 2018, Epilepsy Research.

[15]  E. Grigoriev,et al.  CLINICAL PATHOPHYSIOLOGY OF CEREBRAL EDEMA (PART 2) , 2017 .

[16]  A. Depaulis,et al.  Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy , 2016, CNS neuroscience & therapeutics.

[17]  F. Hock Drug Discovery and Evaluation: Pharmacological Assays , 2016, Springer International Publishing.

[18]  R. Tapia,et al.  Epilepsy and hippocampal neurodegeneration induced by glutamate decarboxylase inhibitors in awake rats , 2015, Epilepsy Research.

[19]  V. Funck,et al.  Contrasting effects of Na+, K+-ATPase activation on seizure activity in acute versus chronic models , 2015, Neuroscience.

[20]  A. Constanti,et al.  Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions. , 2015, Current drug targets.

[21]  Andrey Shilnikov,et al.  Electrogenic properties of the Na⁺/K⁺ ATPase control transitions between normal and pathological brain states. , 2015, Journal of neurophysiology.

[22]  J. Teitelbaum,et al.  Lidocaine for status epilepticus in adults , 2015, Seizure.

[23]  G. R. de Lores Arnaiz,et al.  Brain Na+, K+-ATPase Activity In Aging and Disease , 2014, International journal of biomedical science : IJBS.

[24]  K. Borowicz,et al.  Antiarrhythmic drugs and epilepsy , 2013, Pharmacological reports : PR.

[25]  G. Raszewski,et al.  Enalapril enhances the anticonvulsant activity of lamotrigine in the test of maximal electroshock. , 2013, Pharmacological reports : PR.

[26]  Nishith Singh,et al.  Camphor poisoning-An unusual cause of seizure. , 2012, Medical journal, Armed Forces India.

[27]  R. Olsen Picrotoxin-like channel blockers of GABAA receptors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Anne T. Berg,et al.  Epidemiology in Epilepsy. , 2001, Epilepsy currents.

[29]  A. Carvalho,et al.  Effect of ouabain on the gamma-[3H]aminobutyric acid uptake and release in the absence of Ca(+)+ and K(+)-depolarization. , 1990, The Journal of pharmacology and experimental therapeutics.